A 2-Stage Adaptive Design, Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal and Thigh Subcutaneous Fat (Stage 2)
Latest Information Update: 17 Mar 2025
At a glance
- Drugs CBL-514 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Caliway Biopharmaceuticals
Most Recent Events
- 12 Mar 2025 According to a Caliway Biopharmaceuticals media release, study is expected to be officially published in ASJ in Q2 2025.
- 12 Mar 2025 Results presented in a Caliway Biopharmaceuticals Media Release.
- 12 Mar 2025 According to a Caliway Biopharmaceuticals media release, results of this study have been accepted for publication in the Aesthetic Surgery Journal (ASJ).